A patient with systemic sclerosis presenting with musculoskeletal involvement — a recognised complication that requires targeted therapeutic consideration within the broader management of the disease.
The evidence-based protocol for this scenario includes a specific disease-modifying agent directed at the musculoskeletal manifestations of systemic sclerosis. The full regimen — including selection criteria, monitoring, and sequencing — is detailed in the structured protocol.
DOI: 10.1136/ard-2024-226430
Methotrexate should be considered for the treatment of musculoskeletal involvement in SSc.
View source ↗